Purpose of this Study
We are doing this study to find out if an experimental drug called NT-101 (the study drug) is a safe and effective option for people with wet age-related macular degeneration (AMD). The study drug is a topical solution that is administered directly to the eye (eye drops).
Who Can Participate?
Eligibility
Adults ages 50+ who:
- Are diagnosed with wet AMD
- Do not have diabetes
- Do not have high blood pressure that is not controlled with medication
Age Range
50-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
If you choose to join the study, you will get a random assignment (like a coin flip) to 1 of 2 groups:
- You will either get a 0.05 mM dose of the study drug; OR
- You will get a 0.2 mM dose of the study drug
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
Yes
Spanish Materials Available
No
Study Details
Full Title
A Randomized, Open-Label, Parallel-group, Multicenter Phase 1/2 Study to Evaluate the Safety and Exploratory Efficacy of NT-101 Topical Ophthalmic Solution in Patients with Wet Age-Related Macular Degeneration (AMD) - NT101-AMD-001
Principal Investigator
Lejla
Vajzovic
Protocol Number
PRO00116968
NCT ID
NCT06704009
Phase
I/II
Enrollment Status
Pending Open to Enrollment